Expertise in
22
conditions

Mauricette C. Michallet

Pierre Bénite Université Claude Bernard Lyon I Faculté De Médecine Lyon Est, 
Lyon, FR 
Expertise in
22
conditions
Pierre Bénite Université Claude Bernard Lyon I Faculté De Médecine Lyon Est, 
Lyon, FR 

Overview

Mauricette Michallet practices practicing medicine in Lyon, France.

Michallet is highly rated in 22 conditions, according to our data. Their clinical expertise encompasses Leukemia, Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Chronic Myelogenous Leukemia (CML), and Bone Marrow Transplant.

They are actively involved in clinical research, co-authoring 238 peer reviewed articles and participating in 8 clinical trials.

Locations

Pierre Bénite Université Claude Bernard Lyon I Faculté De Médecine Lyon Est, Lyon, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)
Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)
Enrollment Status: Completed
Publish Date: May 26, 2026
Intervention Type: Drug
Study Drug: Nilotinib
Study Phase: Phase 2
A Multicentre, Open-label Phase II Trial Evaluating the Safety and Efficacy of Ponatinib Induction Followed by Imatinib Maintenance in Adult Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) ≤ 65 Years
A Multicentre, Open-label Phase II Trial Evaluating the Safety and Efficacy of Ponatinib Induction Followed by Imatinib Maintenance in Adult Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) ≤ 65 Years
Enrollment Status: Active_not_recruiting
Publish Date: November 18, 2025
Intervention Type: Drug
Study Drugs: Ponatinib, Imatinib
Study Phase: Phase 2
Impact on Quality of Life of an Early Management Supportive Care of Patients With Acute Leukemia in First Relapse.
Impact on Quality of Life of an Early Management Supportive Care of Patients With Acute Leukemia in First Relapse.
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Other
Study Phase: Not Applicable
Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Low or Intermediate-1 Myelodysplastic Syndrome: A Prospective Multicenter Phase II Study Based on Donor Availability on Behalf of the GFM & SFGM-TC
Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Low or Intermediate-1 Myelodysplastic Syndrome: A Prospective Multicenter Phase II Study Based on Donor Availability on Behalf of the GFM & SFGM-TC
Enrollment Status: Completed
Publish Date: August 02, 2024
Intervention Type: Other
Study Phase: Not Applicable
An Interventional Prospective Study to Test the Feasibility of an Individualized Physical Activity Program in Patients Over 65 Years of Age With Hematologic Malignancies: the OCAPI Project.
An Interventional Prospective Study to Test the Feasibility of an Individualized Physical Activity Program in Patients Over 65 Years of Age With Hematologic Malignancies: the OCAPI Project.
Enrollment Status: Completed
Publish Date: August 30, 2023
Intervention Type: Other
Study Phase: Not Applicable
Clinical Phase III Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Reduced-intensity Conditioning (RIC) Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With AML or MDS Considered Ineligible to Standard Conditioning Regimens
Clinical Phase III Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Reduced-intensity Conditioning (RIC) Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With AML or MDS Considered Ineligible to Standard Conditioning Regimens
Enrollment Status: Completed
Publish Date: July 30, 2020
Intervention Type: Drug
Study Phase: Phase 3
Efficacy of Prophylactic Low Level Laser Therapy (LLLT) Performed by Nurses for Decreasing Severity of Oral Mucositis During Hematopoietic Stem Cell (HSC) Transplantation : a Randomized Double Blind Multicenter Prospective Phase III Trial
Efficacy of Prophylactic Low Level Laser Therapy (LLLT) Performed by Nurses for Decreasing Severity of Oral Mucositis During Hematopoietic Stem Cell (HSC) Transplantation : a Randomized Double Blind Multicenter Prospective Phase III Trial
Enrollment Status: Completed
Publish Date: January 29, 2020
Intervention Type: Device
Study Phase: Phase 3
Allogeneic Hematopoietic Stem Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-thymocyte Globulin for Older Patients With Relapsed Lymphoid Malignancies
Allogeneic Hematopoietic Stem Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-thymocyte Globulin for Older Patients With Relapsed Lymphoid Malignancies
Enrollment Status: Completed
Publish Date: April 05, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

238 Total Publications

Deferasirox 6 months after allo-HSCT in AML/MDS: a prospective propensity-matched study.
Deferasirox 6 months after allo-HSCT in AML/MDS: a prospective propensity-matched study.
Journal: Blood advances
Published: October 27, 2025

Frequently Asked Questions about Mauricette C. Michallet

Is Mauricette C. Michallet a top-rated expert for Bone Marrow Transplant?

MediFind is an objective health platform that identifies experts based on real-world data. Mauricette C. Michallet is classified as an Elite expert for Bone Marrow Transplant, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Mauricette C. Michallet participate in research or clinical trials?

Yes. Mauricette C. Michallet has published 238 articles and abstracts on conditions like Bone Marrow Transplant. You can view a list of Mauricette C. Michallet's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Michallet's expertise for a condition
ConditionClose
View All 14 Advanced Conditions
View All 23 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile